ReviewTranslational andrology and urology2021
Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions.
Review in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.The Journal of urology · 2023Guideline
- Detecting disease associated biomarkers by luminescence modulating phages.Scientific reports · 2022Trial
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Article
- Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate Cancer.JU open plus · 2026Article
- A Semen Panel Signature Comprising sTWEAK Cytokine Levels and Expression of exomiR-221-3p and exomiR-222-3p for Assessing Prostate Cancer Prognosis, Diagnostic Utility, and Detection of Upgrading During Active Surveillance.The Journal of urology · 2026Article
- Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.The journal of liquid biopsy · 2025Review
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine.The Journal of urology · 2025Article
- Article
- Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.Prostate cancer and prostatic diseases · 2025Review
- The Impact of Prostate-Specific Antigen and Gleason Scores on Cardiovascular Death in Prostate Cancer Patients after Radiotherapy or Chemotherapy: A Population-Based Study.Reviews in cardiovascular medicine · 2025Article
- Development and validation of a prostate cancer risk prediction model for the elevated PSA population.Frontiers in oncology · 2025Article
- Circulating biomarkers for diagnosis and response to therapies in cancer patients.International review of cell and molecular biology · 2025Review
- Prostate cancer biomarkers: from early diagnosis to precision treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Article
- Management of Patients With a Negative Multiparametric Prostate MRI Examination:AJR. American journal of roentgenology · 2024Review
- Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.JAMA oncology · 2024Article
- Prostate tumor markers: diagnosis, prognosis and management.Genetics and molecular biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically significant [Grade Group (GG) ≥2] cancer, however, screening carries substantial risks, including frequent unnecessary prostate biopsies and overdetection of non-aggressive cancers. To that end, serum and urine biomarkers with improved specificity for GG ≥2 cancer have been proposed for clinical use following PSA. In the current article, we present clinical validation data for five such biomarkers: PHI, 4Kscore, SelectMDx, ExoDx, and MPS. For all studies, we specify the study population (overall biopsy referral
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.